Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

VV Hindenburg

CFO just sold $39M of stock and leap is just based on Jim Cramer's word and phase 2 trials of a new CF drug.

Vertex is on the leading edge for new cures of many dieases and inflections. Maybe the year of stocks ending with an 'x' is back. Micro-cures could be the answers to what ails us.

Charting a dbl top breakout

Positioned to become the leading Cystic Fibrosis franchise. 2013 a transition year as HCV franchise rolls off.

Nasdaq in maximums.

Trading Vertex now is like the old days, when the valuation rose and fell based on prospects rather than sales. It's pretty clear that Incivek isn't the yellow brick road to sustained profitability that it appeared to be a couple of years ago. Now that Vertex is becoming a spec stock again, it's uncertain how far the share price could retreat. I still like the potential of interferon-free Incivek regimens, the cystic fibrosis franchise, and late stage trials of JAK inhibitor VX-509 in RA and influenza.

It's better this way please.

over 20 period moving average

Unduly crushed by market and very bad news from DNDN, but totally diff story than DNDN, not reliant on Medicare and 70% effective at curing the HEP-C disease. Possible take over and it got a head start on Merck even though Merck was approve slight before (and is less effective)

earnings positive in 2012 with a blockbuster drug funding the pipeline http://www.vrtx.com/current-projects/drug-candidates/pipeline.html and excess cash . I own it.

Vertex's blockbuster drug Telaprevir, which is used for the treatment of Hepatitis C has a 1 in 3 chance of causing a scarring rash that is so bad that treatment must be stopped. Another drug that has a similar mechanism of action that has just been released, Boceprevir, is also used for the treatment of Hepatitis C is also effective without the scarring rash. Physicians will chose Boceprevir as they do not want the additional burden of grading patients scars as well as the high likelihood of stopping treatment.

blockbuster drug

Hopefully, the FDA will approve their Hep C drug.

Vetrex is developing an oral therapy (VX-770) that increases the function of the defective protein that causes cystic fibrosis (CF), a life threatening disease for children. . People that develop CF have mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) that diminish lung function.

The primary endpoint, improved lung function, was met in the phase 3 study of VX-770 in the study population of children (ages 6 to 11 years) with the identified G551D mutation in the CFTR gene. Vertex is expected to file in the US and Europe for marketing approval in late 2011.

Additionally, phase 2 clinical trials are ongoing evaluating the combination of VX770 with a second drug in development (VX-809) that targets the F508del mutation and promotes CFTR proteins reaching the cell surface in normal amounts.

The availability of a therapy that improve lung function by normalizing CFTR function and expression will benefit the roughly 100,000 people worldwide currently affected with CF.

Recently had a positive trial on a cystic fibrosis drug candidate which is why their stock is so high right now, but this comes only a few months before the scheduled date for the FDA decision on their Hepatitis C drug, Telaprevir. Which has a 75% cure rate with no real restrictions and very little competition (and what competition there is doesn't have such a large cure rate). It's a buy for sure, but there will be a dip because there always is in biotech after a success.

New patent should increase revenue

Merc cleared the path for talap...good results on CF....tough burn rate, but when talap hits market look for a decent jump.

Life changing research